Perinatal estrogen exposure elicits a wide range of abnormalities in the female genital tract. Since angiogenesis is essential for morphogenesis, we investigated the vascular density, integrity of vasculatures, and expression of angiogenic factors and their receptors in the uteri of mice treated with diethylstilbestrol (DES) neonatally (DES-mice); the uteri were collected from Day 4 to Day 20. DES treatment reduced the number and density of vasculatures immunostained with PECAM1 (platelet and endothelial cell adhesion molecule 1) in the stroma. Horseradish peroxidase injected into the left ventricle leaked into the endometrium and myometrium on Day 10 in the DES-mice but not in the controls. Electron microscopy confirmed the immaturity of the capillaries, which had an incomplete basal lamina and fewer pericytes. Immunohistochemical studies demonstrated that VEGFA (vascular endothelial growth factor A) expression and ANGPT1 (angiopoietin 1) expression were down-regulated in the stromal cells until Days 20 and 10, respectively. The number of vasculatures with ANGPT2 immunoreaction was reduced in the DES-mice. DES treatment suppressed the expression of VEGFR2 (VEGF receptor 2) and the co-receptor NRP1 (neuropilin 1) as well as TEI2 in the vasculatures. The results of RT-PCR and Western blotting supported the down-regulation of the expression of angiogenic factors and their receptors in DES-mice, whereas the VEGFR1 protein expression was up-regulated. These results suggested that the low concentration of angiogenic factors in the stroma was primarily responsible for the low vascular density in the stroma of the DES-mice, and that the low vascular density and immature vasculatures resulted in uterine malformations. ANGPT1, ANGPT2, DES, NRP1, TIE2, uterus, vascular density, VEGFA, VEGFR1, VEGFR2
INTRODUCTION
Estrogens are essential to the maturation and reproductive functions of the female genital tract, although morphogenesis during postnatal development is thought to be independent of ovarian steroids [1] . However, perinatal estrogen exposure elicits a wide range of abnormalities. Studies using rodents have demonstrated that treatment with the synthetic estrogen diethylstilbestrol (DES) or other estrogens during critical periods of development induces distinct and permanent alterations in the Mullerian duct-derived structures of the female genital tract and influences the incidence of adenocarcinoma [2, 3] . Malformations in the uteri are observed within several days after DES treatment and are retained throughout life, whereas the incidence of adenocarcinoma in the genital tract of DES-treated mice increases in a time-and dose-related manner and depends on postpubertally secreted estrogens [4] .
In the uteri of mice treated with DES (DES-mice) neonatally, the uterine diameter is relatively small, the uterine glands and muscular layers are poorly developed, and collagen fibers accumulate in the endometrial stroma [4, 5] . Studies using mutant mice have suggested that Wnt (Wingless int) and Hox (homeobox) gene products participate in the morphogenesis of the genital tract, since Hox11a, Wnt5a, and Wnt7a knockout mice exhibit reproductive tract phenotypes comparable to those induced by perinatal DES exposure [6] [7] [8] . Although the expression patterns of these genes were reportedly changed in the neonate during DES treatment [5, 9] , whether a direct relationship exists between malformations of the reproductive tract and the expression of these genes is unclear.
Therapontos et al. [10] clearly demonstrated that the primary cause of thalidomide-induced limb malformations was a loss of vasculature in the developing limb. We reported that blood vessels are scanty in the uterine stroma of DESmice, using immunohistochemistry for PECAM1 (platelet and endothelial cell adhesion molecule 1)/CD31, and suggested that one of the mechanisms of malformation might be a low vascular density [5] . The central regulators of angiogenesis consist of two families of growth factors: the VEGFA (vascular endothelial growth factor A) and ANGPT (angiopoietin) families [11] [12] [13] . VEGFA and the receptor VEGFR2 (VEGF receptor 2)/KDR (kinase insert domain protein receptor), a membrane-bound tyrosine kinase, are thought to be the primary mediators of endothelial cell proliferation, and VEGFR1/FLT1 (FMS-like tyrosine kinase 1) is thought to be a negative regulator of VEGFA action. NRP1 (neuropilin 1) is known to act as a co-receptor for VEGFR2 and to enhance VEGFA 165 activity [11] . ANGPT1 and ANGPT2 have also been described as endothelial cell-specific growth factors involved in the maturation, stabilization, and remodeling of vessels, and these growth factors bind to the receptor TIE2 (tyrosine kinase with immunoglobulin-like and EGF-like domain 2)/TEK (endothelial-specific receptor tyrosine kinase), a tyrosine kinase located on the membrane of endothelial cells [11, 14] . ANGPT1 stabilizes and matures blood vessels by recruiting pericytes and vascular smooth muscle cells. ANGPT2 acts as an antagonist of ANGPT1 and is thought to destabilize blood vessels and to promote angiogenesis, although formed blood vessels undergo degradation in the absence of VEGFA.
In the present study, we investigated the blood vessel density, integration, and maturation, as well as the expression of, angiogenic factors and their receptors to elucidate the mechanisms responsible for angiogenic suppression in the uteri of DES-mice. DES-mice collected from Day 4 to Day 20 were examined to avoid the effects of endogenous steroids [15] . First, the blood vessels were immunostained with PECAM1 antibody, and the vascular density was quantitatively measured using image analysis. Second, the leakage of horseradish peroxidase (HRP) from the vasculatures into the uterine tissues and the ultrastructure of the vasculatures were examined to study the vascular integrity and maturation. Third, immunohistochemical double staining for PECAM1 and ssDNA (single strand DNA) or PECAM1 and PCNA (proliferating cell nuclear antigen) was performed to demonstrate whether the inhibition of angiogenesis was caused by the apoptosis of endothelial cells or the suppression of proliferation. And fourth, the spatiotemporal expressions of VEGFA, ANGPT1, and ANGPT2 and their receptors (VEGFR1, VEGFR2, NRP1, and TIE2) were studied using immunohistochemistry, Western blotting, and RT-PCR.
MATERIALS AND METHODS

Tissue Preparation
DES treatment. Pregnant CD-1 mice obtained from Clea Japan Inc. (Tokyo) were housed at 218C-228C with a 12L:12D cycle at the Keio University Animal Facility, Tokyo, Japan. All the animals were maintained and treated according to protocols approved by the Keio University Animal Care Committee. The mice were injected (s.c.) with 4 lg of DES (Sigma-Aldrich, Inc., St. Louis, MO) dissolved in 0.02 ml of sesame oil (Sigma-Aldrich) or the vehicle alone for 5 days, starting within 24 h after birth; the day of birth was regarded as Day 1. The animals in each experimental group were killed on Day Injection and detection of HRP. Under Nembutal (Dainippon Pharmaceutical Co. Ltd., Osaka, Japan) anesthesia, three mice in each group were injected with 50 ll of HRP solution (type IV; 5 mg/ml in saline; SigmaAldrich) into the left ventricle on Days 10 and 20 and then killed after 15 min. The uteri were cut into small pieces and fixed with 2% glutaraldehyde/0.1 M phosphate buffer (pH 7.2) for 2 h at 48C. The tissue blocks were washed with PBS, mounted in OTC compound, and then frozen. Frozen sections (10 lm thick) mounted on a slide glass were incubated with imidazole-3, 3 0 -diaminobenzidine (DAB) solution to detect HRP localization.
Immunohistochemistry
Frozen sections (6 lm thick) were mounted on a new silane-coated slide glass (Muto Pure Chemicals, Tokyo, Japan); fixation, antigen retrieval, and immunostaining for each antigen were then performed as follows [16, 17] . To localize PECAM1, the sections were fixed with 10% formalin/0.1 M phosphate buffer (pH 7.4) for 10 min at room temperature. For the detection of VEGFA, ANGPT1, ANGPT2, VEGFR1, VEGFR2, NRP1, and TIE2, the sections were fixed with 10% formalin containing 25 mM CaCl 2 in 0.1 M HEPES buffer (pH 7.4) for 5 min and briefly washed with distilled water. To localize VEGFR1 and TIE2, the sections were further treated with 100 mM 2-mercaptoethanol in 20 mM Tris-HCl buffer (TB; pH 9.0) for 60 min at room temperature, and then with 100 mM iodoacetamide in 100 mM TB (pH 9.0) for 15 min. Heat-induced antigen retrieval was then performed as follows. The sections were maintained at about 958C for 30 min in 20 mM TB (pH 9.0) for the localization of ANGPT2, VEGFR1, VEGFR2, NRP1, and TIE2, or in 10 mM glycine-HCl buffer (pH 3.0) for the detection of VEGFA and ANGPT1. The fixed or fixed and antigen-retrieved sections were then treated with 1% bovine serum albumin (BSA)/PBS for 1 h at room temperature. For VEGFA and ANGPT1 immunohistochemistry, the sections were treated with 2% skim milk dissolved in PBS. The sections were then incubated with primary antibodies diluted with the respective blocking solution overnight at 48C: anti-PECAM1 rat monoclonal antibody (557355; 1:2000; BD Biosciences, Franklin Lakes, NJ), anti-VEGFA rabbit antibody (sc-507; 1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), anti-ANGPT1 rabbit antibody (ab8451; 1:1000; Abcam, Cambridge, U.K.), anti-ANGPT2 rabbit antibody (ab65835; 1:1000; Abcam), anti-VEGFR1 rabbit antibody (sc-316; 1:200; Santa Cruz), anti-VEGFR2 goat antibody (V-1014; 1:1000; Sigma-Aldrich), anti-NRP1 rabbit monoclonal antibody (ab81321; 1:1000; Abcam), and anti-TIE2 rabbit antibody (sc-324; 1:250; Santa Cruz). For the immunohistochemistry of VEGFR2 and PECAM1, the sections were successively treated with anti-goat Ig rabbit IgG (55346; 1:500; MP Biochemicals, Aurora, OH) and anti rat-IgG rabbit IgG (BA-4001; 1:500; Vector Laboratories, Burlingame, CA) for 30 min, respectively. The sections were then incubated with EnVisionþSystem-HRP (rabbit or mouse; DakoCytomation, Glostrup, Denmark) for 1 h at room temperature. The peroxidase enzyme activity was detected using imidazole-DAB solution [18] . IgG from nonimmunized animals was employed for the control immunostaining. Some sections were counterstained with hematoxylin.
Double Staining of PECAM1 with PCNA or ssDNA
After PECAM1 localization was demonstrated using the DAB reaction (brown color) as described above, the sections were fixed with 10% formalin containing 25 mM CaCl 2 /0.1 M HEPES buffer (pH 7.4) for 5 min at room temperature and briefly washed with distilled water. The sections were heated in 20 mM TB (pH 9.0) at 958C for 15 min for PCNA detection, and in 10 mM citrate buffer (pH 7.0) at 708C for 10 min for ssDNA localization. After washing with PBS, the sections were treated with 1% BSA/PBS for 30 min, then incubated with anti-PCNA (P8825 monoclonal antibody; 1:40 000; SigmaAldrich) or anti-ssDNA (OE-912 rabbit antibody; 1:1000; Immuno-Biological Laboratories Co., Ltd., Gunma, Japan) overnight at 48C. The sections were then incubated with EnVisionþSystem-HRP for 1 h, and each antigen was localized using Ni-Co-DAB solution (purple) [19] .
Electron Microscopy
Four animals in each experimental group were killed on Days 6, 10, and 15. Uterine blocks (1 mm 3 ) were fixed in the standardized fixatives and embedded in LR-White resin according to the procedures described by Yamashita et al. [16] . Ultrathin sections on a nickel grid were treated with 2% glutaraldehyde containing 0.05% tannic acid in 0.1 M phosphate buffer (pH 5.5) for 5 min, and then electronstained with 1% osmium tetroxide in 0.1 M phosphate buffer (pH 7.4), uranyl acetate, and finally lead citrate, as described previously [16] . The sections were examined with a JEOL 1200 EX-II electron microscope (JEOL, Tokyo, Japan) at 80 kV.
Vascular Density Measurement
Photomicrographs of uterine cross sections immunostained with anti-PECAM1 antibody were taken and processed using ImageJ software (http:// imagej.nih.gov/ij/) to measure the ratio of the blood vessel area to a given tissue area. Briefly, digital images from 11 to 15 different sections obtained in each experimental group were thresholded according to the labeling density of PECAM1-immunostaining to distinguish the blood vessel area. Then, the endometrial stroma and myometrium were manually selected, and the ratio of the blood vessel area to the specified area was calculated. The processing steps were automated using a macro routine of the ImageJ software.
RT-PCR
Frozen samples were homogenized in Isogen (Nippon Gene Co. Ltd., Tokyo, Japan) using a Potter-Ervehjem homogenizer (product code 812-771-02; Ikemoto Scientific Technology Co., Ltd., Tokyo, Japan), and the total RNA was prepared according to the manufacture's protocol and evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Complementary DNAs were synthesized from 1 lg of total RNA with reverse transcriptase, RevaTra Ace (Toyobo Co. Ltd., Osaka, Japan), at 428C for 60 min. The cDNAs were amplified by PCR with ExTaq DNA polymerase (Takara Bio Inc., Shiga, Japan) using the following forward (F) and reverse (R) primers, respectively: VegfA, CAGGCTGCTGTAACGATGAA (F) and CACCGCCTTGGCTTGTCACA (R); Angpt1, GGGGGAGGTTGGACAG TAAT (F) and CGAACCACCAACCTCCTGTT (R); Angpt2, GTCCAT GAAGGAGCAGAAGG (F) and GCCTTGATCTCCTCTGTGGA (R); Vegfr1, GAG AGC ATC TAT AAG GCA GCG GAT T (F) and CAC GTT TAC AAT GAG AGT GGC AGT G (R); Vegfr2, TACACAATTCAGAGC GATGTGTGGT (F) and CTGGTTCCTC CAATG GGATATCTTC (R); Nrp1, TGGTCTGGATGGTGGTTGGGC (F) and AAGAGAGG AAAAAAGGG YAMASHITA ET AL.
GGCT (R); Tie2, CCTTCCTACCTGCTA (F) and CCACTACACCTTT CTTTACA (R); and b-Actin, GAGCTGCCTGACGGCCAGGT (F) and TACTCCTGCTTG CTGATCCA (R). RT-PCR analyses of each sample were performed at least four times.
Western Blot Analysis
Protein samples were prepared from the organic phase and the inter phase of the RNA extraction, according to the protocol of Nippon Gene. Proteins were finally dissolved with 1% SDS, and the protein concentration was measured using a wide-range protein quantification kit (product code PQ02; Dojindo Laboratories, Kumamoto, Japan). Each sample was subjected to SDS-PAGE using 12.5%, 10%, or 8% gels; precision plus protein standards (BioRad Laboratories, Hercules, CA) were used as molecular weight standards. The gel samples were electrophoretically transferred to a polyvinylidene difluoride membrane or were transferred with diffusion blotting to enable the detection of VEGFA according to the method reported by Horigome et al. [20] . The membrane was treated with 3% skim milk/PBS for 1 h at room temperature and was subsequently treated with the primary antibodies overnight at 48C with gentle shaking. The primary antibodies were diluted with the following buffers: b-actin (1:5000), VEGFR1 (1:500), VEGFR2 (1:1000), NRP1 (1:1000), and TIE2 (1:2000) in 0.05% Tween 20/PBS (TPBS) containing 1% BSA; VEGFA (1:500) and ANGPT2 (1:1000) in 0.5M NaCl, 0.05% Tween 20/10 mM TB, pH 7.4 (TTBS-2) containing 1% BSA; and ANGPT1 (1:4000) in Can Get Signal solution 1 (Toyobo Co. Ltd.) containing 1% BSA. The membrane was washed with TTBS-2 and incubated with EnVisionþSystem-HRP diluted with TPBS (1:200) for 1 h. For the detection of VEGFR2, the membrane was treated with anti-goat Ig rabbit IgG (1:5000) for 1 h prior to incubation with EnVisionþSystem-HRP. After washing with TPBS, the HRP enzyme activity was detected using an enhanced chemiluminescence method (Thermo Scientific 
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Inc., Rockford, IL). Expression of each protein was examined using at least three blots.
Statistical Analysis
All the statistical analyses were performed using a two-tailed Student t-test. P values less than 0.05 were considered statistically significant. Data were presented as the mean values with the SD.
RESULTS
Distribution of Blood Vessels and Vascular Density
The distribution of the blood vessels was visualized using the antibody to PECAM1 (Fig. 1 ). In the vehicle-treated control animals, the blood vessels were highly branched in the outer longitudinal muscular layer of the mesometrial pole (Fig. 1, a  and b) , and the main blood vessels ran between the inner circular and outer longitudinal muscular layers (Fig. 1, a, c, e, and g). The vessels then penetrated the inner muscular layer and branched into the deep portion of the stroma, then became distributed throughout the endometrial stroma between Days 4 and 20. The number of blood vessels in the endometrium of the DES-mice was lower than that in the control animals during development (Fig. 1, b, d , f, and h). In particular, the superficial stroma was avascular on Day 6 in the uteri of DES-mice (Fig.  1b) . The distribution of blood vessels between the two muscular layers was disturbed, and blood vessels were present not only between the two muscular layers but also in the myometrium and the subserosa on Days 10 and 15 ( Fig. 1, d and f). The veins located in the mesometrial pole were usually dilated on all the experimental days (Fig. 1h) . Large blood YAMASHITA ET AL. vessels were seen between the two muscular layers on Day 20 (Fig. 1h) .
In the control animals, both the endometrial stromal area and the areas of the myometrial and perimetrial layers increased with advancing age (Fig. 2A) , and the PECAM1-positive areas in the endometrial stroma and the myometrial and perimetrial layers similarly increased with maturation (Fig.  2B) . However, in the DES-mice, the stromal area and the areas of the myometrial and perimetrial layers reached a maximum on Days 10 and 15, respectively ( Fig. 2A) . The PECAM1-positive area remained almost constant in the endometrial stroma and reached a maximum in the myometrial and perimetrial layers on Days 10 and 15 (Fig. 2B) . The vascular density in the stroma was significantly higher in the control animals than in the DES-mice during development (P , 0.001); in particular, the density was 3-to 4-fold higher on Days 6 and 10 ( Fig. 2C) . In contrast, the vascular density in the myometrial and perimetrial layers was higher in the uteri of the DES-mice than in those of the control animals from Day 10 to Day 20 ( Fig. 2C ): Day 10, P , 0.03; Days 15 and 20, P , 0.001.
Integrity of Blood Vessels
Blood vessel permeability. In the control animals, HRP injected into the left ventricle was not detected in the uteri on Days 10 and 20 ( Fig. 3, a and c) . In the DES-mice, HRP was localized in the uterine stroma and the myometrial and perimetrial layers on Day 10 ( Fig. 3b) , but not on Day 20 (Fig. 3d) . In the connective tissues of the broad ligament, HRP was hardly detected in either the control or the DES-mice.
Ultrastructure of blood vessels. In the capillaries, pericytes were usually associated with the endothelial cells in the control animals ( Fig. 4a ) but were typically absent in the DES-mice on Days 6 and 10 ( Fig. 4b) . In the DES-mice, endothelial cells that had detached from the basal lamina and cell debris were seen in the blood vessel lumens (Fig. 4c) . Detached endothelial cells were commonly observed on Day 10, but were observed to a lesser extent on Days 6 and 15. The cell membranes of the endothelial cells on the basal lamina were distended and had extruded processes, and the intercellular junctions were poorly developed. Erythrocytes without an endothelial lining were also recognized in a few cases (Fig. 4b) .
Mechanisms of Angiogenesis Suppression
Effect of DES exposure on cell proliferation and apoptosis in the vasculatures. DES treatment reduced the number of PCNA immunostained cells not only in the blood vessels but also in all other cell types (i.e., epithelial, stromal, and myometrial cells) on Days 6 and 10 ( Fig. 5A, a and b) . The number of PCNA-positive cells increased in the blood vessels of DES-mice on Days 15 and 20, and was higher among the epithelial cells and lower among the endometrial stromal and myometrial cells, compared with the control animals (Fig. 5A,  c and d) . From Day 6 to Day 20, ssDNA immunostained cells (indicating apoptotic cells) were not observed in the vasculature of the stromal and myometrial layers in either the control animals or the DES-mice (Fig. 5B) , although epithelial cells stained with the anti-ssDNA antibody were recognized on all the experimental days in the control animals and on Days 15 and 20 in the DES-mice (Fig. 5Bd) .
Expression of VEGFA and the receptors and co-receptor. Expression of angiogenic factors and their receptors demonstrated with the immunohistochemistry is summarized in Table  1 . Almost the same expression patterns for each antigen were observed on Days 4 and 6, but no significant changes were detected on Day 2 (data not shown).
In the control animals, the luminal epithelial cells exhibited a weak VEGFA immunoreaction in the cytoplasm on Days 4, 6, and 10 and moderate staining on Days 15 and 20; the glandular epithelial cells also showed a positive reaction (Fig.  6, a, c, e, g, and i ). The endometrial stromal cells showed a weak immunostaining, and the myometrial cells showed moderate and almost homogeneous immunostaining on all the experimental days. Vascular smooth muscle cells revealed weak to moderate VEGFA immunostaining. In the DES-mice, VEGFA expression was up-regulated in the epithelial cells on 
ANGIOGENESIS IN UTERI EXPOSED TO DES NEONATALLY
Days 4, 6, and 10, with a strong reaction seen in the Golgi area (Fig. 6, b, d , and f), whereas it was down-regulated on Day 20. VEGFA immunostaining in the DES-mice decreased in the stromal cells on all the experimental days (Fig. 6, b, d , f, h, and j). The VEGFA immunoreaction in the myometrial cells was heterogeneous, showing faint to strong staining on all the experimental days in the DES-mice (Fig. 6, b, d , f, h, and j). Although the vascular smooth muscle cells were positive for VEGFA immunostaining, the number of vasculatures in the endometrial stroma was smaller than that in the control animals until Day 15. (Fig. 7A) . In the control animals, endothelial cells and the vascular smooth muscle cells of arteries, arterioles, and large veins exhibited a positive VEGFR1 immunoreaction on Days 15 and 20 (Fig. 7Ae) . In the epithelial cells, VEGFR1 was present along the basal membrane on Days 6 and 10 ( Fig.  7A, a and c) and along the apical membrane on Days 15 and 20 (Fig. 7Ae) . Myometrial cells exhibited a weak VEGFR1 immunostaining on all experimental days (Fig. 7A, a, c, and e) , and stromal cells showed a moderate immunostaining on Days 15 and 20 (Fig. 7Ae) . In the DES-mice, the endothelial cells and vascular smooth muscle cells of arteries, arterioles, and veins exhibited VEGFR1 immunoreaction on Days 15 and 20 ( Fig. 7Af) and showed a faint reaction in the myometrium on Days 6 and 10. The myometrial cells exhibited a stronger VEGFR1 immunoreaction than the stromal cells from Day 6 to Day 20. VEGFR1 was mainly localized along the basolateral membrane in the epithelial cells on Days 6 and 10 (Fig. 7A, b  and d) , and along the apical membrane on Days 15 and 20 (Fig.  7Af) . No specific immunostaining was observed when normal rabbit IgG was used as the primary antibody in place of anti-VEGRR1 antibody (Fig. 7A, g and h) .
VEGFR1 was
In the control uteri, numerous endothelial cells showing VEGFR2 immunostaining were present in the endometrium and the outer muscular layer of the mesometrial pole from Day 4 to Day 20 ( Fig. 7B, a, c, e, and g ). Blood vessels located between the two muscular layers also exhibited a positive reaction. The distribution pattern during development was almost the same as that of PECAM1. In the uteri of DES-mice, the distribution pattern of the VEGFR2-positive blood vessels was similar to that for PECAM1, and the number of VEGFR2-positive blood vessels in the endometrial stroma was significantly lower than that in the control animals (Fig. 7B,  b, d , f, and h).
In the control mice, NRP1 was found in the endothelial cells and some vascular smooth muscle cells from Day 4 to Day 20 ( Fig. 8, a, c, e, and g ). The myometrial cells exhibited weak reactions on all experimental days. The epithelial cells were negative for NRP1 immunostaining. In the DES-mice, the endothelial cells and vascular smooth muscle cells exhibited NRP1 immunostaining (Fig. 8, b, d, f, and h) . Although the number of NRP1-positive vasculatures in the endometrial stroma gradually increased on Days 15 and 20 (Fig. 8, f and h) , it was lower than that in the control animals. Myometrial cells showed a moderate NRP1 immunostaining on Days 6 and 10 ( Fig. 8, b and d ) and faint to weak staining on Days 15 and 20. On Day 20, some glandular epithelial cells showed a weak immunostaining along the basolateral cell membrane (Fig. 8h,  inset) .
Three transcripts coding for proteins comprised of 188, 164, and 120 amino acids of VEGFA, corresponding to 397-bp, 325-bp, and 193-bp RT-PCR products, were observed in all the sample preparations (Fig. 9A) . The transcript of VEGFA 164 was the major component. The VegfA mRNA level was higher in the uteri of the control animals than in those of the DESmice from Day 4 to Day 20 when the b-actin mRNA level was used as an internal control. Vegfr1 mRNA levels were almost constant from Day 4 to Day 20, and control and DES-mice showed almost the same Vegfr1 mRNA expression. Vegfr2 mRNA expression was higher on all the experimental days in the control animals compared with the DES-mice (Fig. 9A ). The Nrp1 mRNA expression level was higher until Day 10 and lower on Days 15 and 20 in the uteri of DES-mice compared with the levels in the control animals (Fig. 9A) . 
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The anti-VEGFA antibody reacted with a 22-kD polypeptide. On all the experimental days, the VEGFA protein concentration was higher in the uteri of the control animals than in those of the DES-mice when b-actin was used as a standard protein (Fig. 9B) . VEGFR1 antibody reacted with the 150-kD (membrane-bound form) and the 100-kD (soluble form) receptors. The membrane-bound VEGFR1 expression level was higher in the DES-mice than in the control animals, whereas the protein levels of soluble VEGFR1 were almost the same in both groups on each experimental day. VEGFR2 antibody bound with the 230-kD (intact membrane form), 190-kD (truncated membrane form lacking the C-terminal portion), and 150-kD (soluble form) polypeptides in all the specimens (Fig. 9B) . The protein levels of both the membrane and soluble VEGFR2 were higher in the uteri of the control animals than in those of the DES-mice on all the experimental days. The antiNRP1antibody reacted with an approximately 150-kD polypeptide (Fig. 9B) . The reaction was stronger in the DES-mice than in the control animals on Days 6 and 10 but was weaker on Days 15 and 20.
Expression of ANGPT1 and ANGPT2 and their receptor, TIE2. In the control mice, ANGPT1 was mainly localized in the stroma, and faint ANGPT1 immunostaining was present in the epithelial cells and smooth muscle cells (Fig. 10A) . A strong ANGPT1 immunoreaction was seen in the endometrial stroma on the mesometrial pole side on Day 6 (Fig. 10Aa) and in the stroma of the antimesometrial pole side on Day 10 (Fig. 10Ac) ; the deep layer of the stroma was strongly immunostained. ANGPT1 was almost evenly localized in the stroma on Days 15 and 20 (Fig. 10A, e and g ). In the DES-mice, the epithelial cells exhibited a strong ANGPT1 immunoreaction and the endometrial stroma showed a faint reaction on Days 6 and 10 ( Fig. 10A, b and d) . Strong ANGPT1 immunostaining was mainly detected in the stroma on Days 15 and 20 (Fig. 10A, f  and h ).
In the control animals, the ANGPT2 immunoreaction was exclusively present in the vascular endothelial cells located in the stroma and myometrium from Day 4 to Day 20 (Fig. 10B) , whereas the number of vasculatures with a positive ANGPT2 immunoreaction was smaller than the number of vasculatures with a positive VEGFR2 or NRP1 immunoreaction. A weak ANGP2 immunostaining was also seen in the endometrial stroma and in the epithelial cells. In the DES-mice, the endothelial cells showed a positive reaction, and the number of immunostained vasculatures in the myometrium was larger than that in the stroma. Some epithelial cells showed moderate and strong ANGPT2 immunostaining on Days 6 and 10, respectively (Fig. 10B, b and d) .
TIE2 was mainly localized in the endothelial cells of vasculatures and the epithelial cells. In the control animals, the 
a Intensity of immunostaining was demonstrated on a scale of 0-4; 0, 1, 2, 3, and 4 indicate negative, faint, weak, moderate, and strong immunostaining, respectively. b BV (St), blood vessels in the stromal layer; BV (My), blood vessels in the myometrial and perimetrial layers; Ep, epithelial cells; St, stromal layer; My, myometrial layer. c VEGFA immunostaining in the myometrial layer was heterogeneous, showing faint to strong staining. d ANGPT1 immunoreaction was heterogeneous. Endometrial stroma exhibited strong immunoreaction on the mesometrial pole side and weak reaction on the antimesometrial pole side in the DES mice on Day 6. e Uterine stroma showed weak ANGPT1 immunostaining on the mesometrial pole side and strong staining on the antimesometrial pole side in the DESmice on Day 10.
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number of vasculatures immunostained with anti-TIE2 reached to a maximum in the stroma on Day 10 and gradually increased with development in the myometrim (Fig. 11, a, c, e, and g ). TIE2 was localized in the epithelial cells along the apical membrane (Fig. 11, e and g ). In the DES-mice, the number of TIE2-positive blood vessels was smaller in the stroma and larger in the myometrium than that in the control animals on Days 6 and 10 ( Fig. 11, b and d) , and the number in both stromal and myometrial layers increased on Days 15 and 20 (Fig. 11, f and h ). DES treatment up-regulated the TIE2 expression in the epithelial cells on Days 6 and 10 ( Fig. 11, b and d).
Angpt1 mRNA expression was higher until Day 10 and lower on Days 15 and 20 in the uteri of DES-mice compared with the control animals (Fig. 12A) . The Angpt2 mRNA level was higher in the DES-mice than in the control animals on Days 4 and 6, although the Angpt2 mRNA expression level was relatively low in the DES-mice after Day 8 (Fig. 12A) . The Tie2 mRNA level was higher in the uteri of the control animals YAMASHITA ET AL. than in those of the DES-mice on each experimental day (Fig.  12A) .
The anti-ANGPT1 antibody recognized a single 58-kD polypeptide. The ANGPT1 protein level was lower on Day 6 and slightly higher on Day 10 in the control animals than in the DES-mice, but was almost the same on Days 15 and 20 (Fig.  12B) . The antibody to ANGPT2 reacted with a 64-kD polypeptide, and the expression pattern of ANGPT2 was almost the same as that of ANGPT1 (Fig. 12B) . The anti-TIE2 antibody recognized a 150-kD polypeptide. On all the experimental days, the TIE2 polypeptide concentration was higher in the uteri of the control animals than in those of the DES-mice (Fig. 12B) .
DISCUSSION
The present study demonstrated that the vascular density in the endometrial stroma was significantly lower in the DESmice than in the control animals on all the experimental days (P , 0.001; Fig. 2) , and the vasculatures, particularly the capillaries, were immature and exhibited a low integrity until Day 15. Therapontos et al. [10] have shown that the primary cause of thalidomide-induced limb malformations is the loss of vasculature in the developing limb, and the malformations are induced within a short, time-sensitive developmental window, similar to the situation for DES-induced malformations. The corneal neovascularization of thalidomide-treated rabbit is reportedly immature, with poorly formed cell junctions, an incomplete basal lamina, and fewer associated pericytes [21] . These results strongly suggest that the angiogenic suppression in the endometrial stroma is primarily responsible for the uterine malformations in the DES-mice. Double immunostaining for PECAM1 and PCNA and for PECAM1 and ssDNA demonstrated that DES treatment suppressed the proliferation of uterine vasculature cells but did not induce the apoptosis of vasculature cells (Fig. 5) . Since angiogenesis is mainly regulated through two signaling systems, i.e., VEGFAmediated and ANGPT-mediated systems [11] [12] [13] , the spatiotemporal expression of VEGFA and ANGPT and their receptors was examined to elucidate the mechanism of angiogenic suppression in the stroma.
VEGFA was localized in the epithelial cells, endometrial stromal cells, myometrial cells, and vasculatures (Fig. 6) . VEGFA expression was down-regulated in the stroma and vasculatures on all the experimental days and was stimulated in the epithelial cells until Day 10 in the DES-mice. The downregulation of VEGFA expression in the DES-mice was also confirmed using Western blotting and RT-PCR. VEGF 165 was shown to be the major isoform of VEGFA using RT-PCR, and only the 22-kD polypeptide, which may be translated from VEGF 165 mRNA, was detected in a Western blot analysis. VEGFA, which is exclusively localized in the Golgi area of 
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epithelial cells during DES stimulation, may be mainly secreted into the uterine lumen. VEGFA localization in the uteri is reportedly influenced by sex hormones [22] [23] [24] . Ma et al. [23] reported that long-term 17b-estradiol (E 2 ) treatment upregulated VEGFA expression in the epithelial cells and down-regulated it in the endometrial stroma of ovariectomized adult mice. Nayak and Brenner [24] demonstrated that VEGFA expression in stromal cells peaked during the midproliferative stage, and they suggested that VEGFA-originating stromal cells are essential for endometrial vascular proliferation in the rhesus macaque. In addition, Fan et al. [25] previously demonstrated that VEGFA Trap significantly inhibited the vascularization of the upper regenerated stroma, but did not alter the number of preexisting vessels in the basal zones or the myometrium of uteri in decidualized mice and rhesus macaques. These data indicate that a low concentration of VEGFA in the endometrial stroma is the primary cause of the low vascular density in the stroma of the DES-mice.
Since the mitogenic actions of VEGFA are mainly mediated by VEGFR2 and the co-receptor NRP1 [12, 13] , and VEGFR1 is thought to be a negative regulator that acts as a decoy receptor for VEGFA [26, 27] , the expression of these receptors was examined. The expression of NRP2 was not studied in this study, since several reports have provided evidence showing that NRP2 plays a key role in lymphangiogenesis [28] . The distribution pattern of VEGFR2 in the vasculatures was almost the same as that of NRP1 and PECAM1. The number of stromal vasculatures immunostained with VEGFR2 and NRP1 was significantly lower in the DES-mice than in the control animals from Day 6 to Day 20 ( Figs. 7B and 8) . The downregulation of VEGFR2 and NRP1 may be due to the decrease in the vascular density in the uteri of DES-mice, although the possibility that DES treatment directly suppresses VEGFR2 and NRP1 expression in endothelial cells and inhibits angiogenesis cannot be ruled out. In the Western blot analysis, the concentrations of the truncated and soluble forms of VEGFR2, which act as decoy receptors for the intact membrane form VEGFR2 [29] , were almost proportional to that of the intact form. The NRP1 immunoreaction was reportedly localized not only in the endothelial cells but also in the nonvascular cells [30, 31] . In the present study, NRP1 was predominantly localized in the endothelial cells and the vascular smooth muscle and myometrial cells. The results from RT-PCR and Western blot analyses indicated that NRP1 expression was up-regulated on Days 6 and 10, possibly reflecting the high NRP1 expression level in the myometrium. Immunostaining for VEGFR1 was detected in many cell types and in the arteries, arterioles, and veins, although it is unclear whether VEGFR1 is present in growing capillaries and directly acts as a negative regulator of angiogenesis in the uterine vasculatures. However, both the membrane form and the soluble form of VEGFR1 may reduce the concentration of active VEGFA in the uteri of DES-mice.
The ANGPT and TIE2 signals are the second mostimportant angiogenic and angiostatic signaling mechanisms. The present study showed that the ANGPT1 concentration in the endometrial stroma was lower in the uteri of DES-mice than in those of control animals on Days 6 and 10, and VEGFA expression was relatively low in the DES-mice on all the experimental days. ANGPT2 expressed in the endothelial cells was also relatively low in the uterine stroma of DES-mice.
TIE2 was localized in the vasculature, and the number of vasculatures showing TIE2 immunostaining in the stroma was lower in the DES-mice than in the control animals. The downregulation of ANGPT1, ANGPT2, and the receptor may also cause the attenuation of angiogenesis, the immaturity of the vasculature, and the destruction of the vasculature in the endometrial stroma of DES-mice [32] . TIE1 expression was not examined in the present study, since it is reported that only TIE2 can form high-affinity complexes with ANGPT, although TIE1 and TIE2 exhibit a high level of structural homology [14, 33] .
The vascular density in the myometrium was relatively high, and the distribution was disordered in the DES-mice. The VEGFA immunoreaction in the myometrial cells was heterogeneous, ranging from faint to strong staining in the DES-mice, particularly on Days 4, 6, and 10, whereas the reaction was moderate and homogeneous in the control animals. A locally high VEGFA concentration in the myometrial layer may cause active angiogenesis, producing the irregular vascular network in the DES-mice. Systemic circulating VEGFA may also stimulate angiogenesis in the relatively large blood vessels located between the two muscle layers, since angiogenesis should be up-regulated in most tissues during development and VEGFA is reported to be secreted from the lungs, kidneys, and liver even in mature rodents [34] . In addition, the vascular density in the myometrial and subserosal layers is presumably overestimated in the DES-mice because the veins, particularly in the mesometrial pole, are enlarged compared with those in the control animals. 
Many studies have shown that E 2 injection increases uterine vascular permeability and endothelial proliferation after several hours and induces epithelial proliferation after 12 h in the uteri of neonates and mature rodents [35] [36] [37] . However, Ma et al. [23] reported that long-term E 2 treatment attenuated angiogenesis in the uteri of ovariectomized adult mice. Daily DES injection suppressed epithelial proliferation and apoptosis, as reported by Huang et al. [38] . Our results obtained in neonatal mice support these findings. Therefore, the long-term and short-term effects of estrogen should be considered separately, and the effects appear to be opposite in most estrogen-induced phenomena in the uteri. These long-term effects may be based not only on the direct effects of estrogens on each cell type, but also on continuous edema and tissue hypoxia.
Although the inductions of malformation and carcinogenesis are assumed to be interdependent, the mechanisms for each alteration have not yet been elucidated. Cooke et al. [39] and Cunha and Young [40] demonstrated that stromal cells play essential roles for the morphogenesis and proliferation of epithelial cells in reproductive tissues in female and male rodents. Several secreted proteins, such as EGF (epidermal growth factor), IGF1 (insulin-like growth factor 1), TGFa (transforming growth factor a), and KGF (keratinocyte growth factor) have been reported to be intermediate factors in the epithelial-stromal interaction [41] [42] [43] [44] . A low vascular density in the stroma should induce tissue hypoxia. Our preliminary study showed that protein-bound pimonidazole, indicating the presence of a low oxygen concentration (less than 10 mmHg), was highly localized in the uterine epithelial cells of DES-mice on Days 6 and 10. Tissue hypoxia presumably changes cellular metabolism and up-regulates hypoxia-inducible gene expression, changing the expression patterns of numerous genes, including those of growth factors in both stromal and epithelial cells. Furthermore, hypoxia presumably provides a suitable environment for the survival and growth of tumor cells [45, 46] . We are now studying whether a low vascular density in the endometrial stroma as well as tissue hypoxia are maintained in the uteri of mature DES-mice.
